Profusa Receives Favorable Nasdaq Listing Determination
Rhea-AI Summary
Profusa (Nasdaq: PFSA) announced that the Nasdaq Hearings Panel granted its request to transfer the listing from The Nasdaq Global Market to The Nasdaq Capital Market by letter dated May 6, 2026.
The Company’s continued Nasdaq listing is conditional on satisfying interim milestones and meeting the Capital Market bid price and stockholders' equity requirements by July 6, 2026.
AI-generated analysis. Not financial advice.
Positive
- Nasdaq approved transfer to the Capital Market tier
- Avoids immediate delisting while remediation proceeds
Negative
- Must meet interim milestones and compliance by July 6, 2026
- Continued listing depends on restoring bid price and stockholders' equity
News Market Reaction – PFSA
On the day this news was published, PFSA gained 5.27%, reflecting a notable positive market reaction. Argus tracked a trough of -5.8% from its starting point during tracking. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $114K to the company's valuation, bringing the market cap to $2.27M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Sector peers show mixed, mostly flat moves and none appeared in the momentum scanner, while PFSA’s move was flagged as stock-specific (target_direction: down).
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| May 05 | Strategic review launch | Positive | -6.6% | Board-led process to evaluate strategic alternatives and maximize shareholder value. |
| Apr 06 | Acquisition LOI | Positive | +144.1% | LOI to acquire PanOmics diagnostics platform for equity and expand into new market. |
| Feb 27 | Financing change | Neutral | -14.8% | Withdrawal of Form S-1 for a $15M offering to pursue a smaller financing. |
| Feb 19 | Guidance increase | Positive | -4.5% | Receipt of Lumee purchase orders and raised 2026 revenue guidance to $1.5M–$3.0M. |
| Feb 12 | Clinical collaboration | Positive | -33.4% | Mayo Clinic collaboration on high-impact clinical applications of Lumee technology. |
Recent PFSA news often saw negative or muted price reactions, even on seemingly positive strategic, partnership, and guidance announcements.
Over the past few months, PFSA reported multiple strategic and commercial steps: a Mayo Clinic collaboration, raised 2026 revenue guidance to $1.5M–$3.0M, withdrawal of a planned $15M offering in favor of a smaller one, a PanOmics LOI near $30M, and a board-led review of strategic alternatives. Despite these, four of the last five news days showed negative 24-hour price reactions, underscoring persistent market skepticism ahead of this Nasdaq listing determination.
Market Pulse Summary
The stock moved +5.3% in the session following this news. A strong positive reaction aligns with relief around the favorable Nasdaq listing determination, which allowed PFSA to transfer from the Nasdaq Global Market to the Nasdaq Capital Market while keeping a path to continued listing. However, past news often saw negative follow-through even on good developments, and the stock traded far below its $180 52-week high before this update, underscoring ongoing execution and compliance risks.
Key Terms
nasdaq hearings panel regulatory
nasdaq global market regulatory
nasdaq capital market regulatory
AI-generated analysis. Not financial advice.
BERKELEY, CA, May 08, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. (“Profusa” or the “Company”) (Nasdaq: PFSA), a digital health company pioneering the next generation of technology platform enabling the continuous monitoring of an individual’s biochemistry, announced that, by letter dated May 6, 2026, the Nasdaq Hearings Panel granted the Company’s request to transfer the listing of its securities from The Nasdaq Global Market to The Nasdaq Capital Market. The Company’s continued listing on Nasdaq is subject to the Company’s satisfaction of certain interim milestones and, ultimately, the Company’s compliance with the bid price and stockholders’ equity requirements for continued listing on the Capital Market tier by July 6, 2026.
About Profusa
Based in Berkeley, CA, Profusa is a commercial stage digital health company led by visionary scientific founders, an experienced management team and a world-class board of directors in the development of a new generation of tissue-integrated sensors to detect and continuously transmit actionable, medical-grade data for personal and medical use. With its long-lasting, injectable and affordable biosensors and its intelligent data platform, Profusa aims to provide people with a personalized biochemical signature rooted in data that clinicians can trust and rely on.
“LUMEE”, “PROFUSA” and the PROFUSA logo are registered trademarks of Profusa, Inc. in the United States, Canada, European Union, China, Japan, South Korea and Australia.
For more information, visit https://profusa.com.
Special Note Regarding Forward-Looking Statements
Certain statements in this press release may be considered “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future events or future financial or operating performance of Profusa. In some cases, you can identify forward-looking statements by terminology such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “forecast,” “future,” “intend,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “propose,” “seek,” “should,” “strive,” “will,” or “would” or the negatives of these terms or variations of them or similar terminology. Forward‑looking statements are based on current expectations and are subject to risks and uncertainties that could cause actual results to differ materially from those described in such statements, including but not limited to the Company’s ability to obtain the required stockholder approvals, execute its compliance plan within the timeframes specified by the Panel, effect and maintain compliance with the Bid Price Rule and other applicable listing requirements, complete anticipated transactions, and other factors described in the Company’s filings with the Securities and Exchange Commission (the “SEC”), including its Annual Report on Form 10‑K for the year ended December 31, 2025, and subsequent Quarterly Reports on Form 10‑Q and Current Reports on Form 8‑K. The Company undertakes no obligation to update any forward‑looking statements, whether as a result of new information, future events or otherwise, except as required by law.
Contacts
Investor and Media Contacts
email: info@coreir.com
phone: 1 (212) 655-0924
